Evicenter
MarkdownMedical informationP&T meetings
Onvuzosiran (ADX-324)

Prophylaxis of hereditary angioedema attacks

Launch
Not announced
Last updated
119 sources

Section 3 of 6

Product information and disease description

205 evidence topics · 82 sources

Product description

Phase of product development

Launch

No evidence found.

Regulatory designations outside the United States

No evidence found.

Product information

Generic, brand name and therapeutic class of product
Brand name

No evidence found.

Dosage forms and strengths
Phase 3 doses and injection volumes
ArmQuoted dose and volume
Onvuzosiran every 6 months“ADX-324 300 mg Q6M (1.5ml)”
Onvuzosiran every 3 months“ADX-324 240 mg Q3M (1.2ml)”
Placebo matched to the 6-month regimen“Placebo (1.5 ml) n=15”
Placebo matched to the 3-month regimen“Placebo (1.2 ml) n=15”
Material safety data sheet

No evidence found.

Average sales price and wholesale acquisition cost

Not applicable.

American hospital formulary service (AHFS), or other drug classification
AHFS classification

No evidence found.

Indication
Pharmacology
Mechanism of action
Pharmacodynamics
Pharmacokinetics
Contraindications/Warnings/Precautions/Adverse effects
Warnings and precautions

Not applicable.

Special populations
Drug/Drug, drug/disease interactions
Effects of other drugs on Onvuzosiran

No evidence found.

Effects of Onvuzosiran on other drugs

No evidence found.

Dosing and administration
Dosage
Administration
Access and distribution
Co-prescribed/Concomitant therapies
Effect of Onvuzosiran on quality measures

No evidence found.

Product comparison
Donidalorsen: mean attack rate per four weeks in OASIS-HAE

Place of product in therapy

Disease description

Definition and etiology
Epidemiology
Incidence of hereditary angioedema
Prevalence of hereditary angioedema
Pooled diagnosed annual prevalence: combined HAE types and 95% confidence interval
Natural history, survival, and mortality
Pathophysiology
Diagnosis
Clinical presentation - signs and symptoms
Long-term morbidity
Burden of hereditary angioedema
Humanistic burden and health-related quality of life
Multinational adult survey: treatment exposure and quality-of-life outcomes
MeasureReported result
Participants included“260”
Participants using any long-term prophylaxis“153 (58.8%)”
First-line prophylaxis among prophylaxis users, per study classification“56/153 (36.6%)”
AE-QoL total score, mean ± SD“42.9 ± 23.2”
Participants with AE-QoL total score ≥39“137 of 260 (52.7%)”
Moderate to severe anxiety by HADS“69 (26.5%)”
Moderate to severe depression by HADS“27 (10.4%)”
Economic burden and healthcare resource utilization
Economic impact of hereditary angioedema on families
Economic impact of diagnostic testing

Approaches to treatment

Current treatment options and standard of care
C1 esterase inhibitors
Plasma kallikrein inhibitors
Bradykinin b2 receptor antagonists
Factor XIIa inhibitors
Prekallikrein-directed antisense oligonucleotides
Attenuated androgens
Antifibrinolytics
Tranexamic acid: reported prophylactic responses in HAE-FXII, HAE-PLG, and HAE with normal C1 inhibitor of unknown cause
Plasma replacement
Progestins
Progestin prophylaxis: variant-specific observational evidence
FeatureGuideline description
Subtype with reported responses“HAE-FXII”
Reported response“Favourable responses”
Evidence for other variants“limited evidence for other HAE-nC1INH variants.”
Supportive care and airway management
Limitations of current therapies
Summary
  • Administration frequency of first-line prophylaxis ranges from twice weekly (subcutaneous plasma-derived C1 inhibitor, every 3 or 4 days) and once daily (oral berotralstat) to every 2 weeks (lanadelumab, with every 4 weeks considered after more than 6 months of good control), monthly after a 400 mg loading dose (garadacimab), and every 4 or 8 weeks (donidalorsen). Intravenous C1 inhibitor requires venous access and has a “high cost” and “frequent administrations due to its short half-life”.
  • Attacks “can still occur even in patients under LTP”. Berotralstat achieved an approximately 50% reduction in attack rate in its pivotal trial, and donidalorsen every 4 and 8 weeks reduced attacks by 81% and 55%, respectively, compared with placebo. Berotralstat, lanadelumab, and donidalorsen have a delayed onset of protection.
  • In US commercial claims, 55% of patients had refill gaps, discontinued, or switched prophylaxis within a year of initiation, and on-demand treatment use “remained present for over two-thirds of patients”. A second study reported that annualized expenditures for on-demand prescriptions, hospitalizations, and emergency department visits averaged more than $200,000 after subcutaneous prophylaxis began.
  • No head-to-head trials of prophylactic agents have been published; a Cochrane review stated that this “prevented us from drawing firm conclusions on the relative efficacy of the drugs”, and indirect comparisons favor lanadelumab and C1 inhibitor over berotralstat.
  • About 50% of patients receive long-term prophylaxis, even in high-income countries, and the higher costs of newer agents limit their availability.
  • Second-line attenuated androgens are associated with virilization in women, dyslipidemia, and hepatotoxicity, cannot be used in pregnancy or in children and adolescents, and require semi-annual laboratory monitoring with annual liver ultrasound; tranexamic acid shows “mediocre efficacy in HAE-C1-INH”.
Place in treatment, anticipated use, and care setting
Summary

A 2026 guideline (Vázquez et al.) recommends that all patients with HAE be evaluated for long-term prophylaxis at every visit through shared decision-making, and lists subcutaneous plasma-derived C1 inhibitor, lanadelumab, berotralstat, garadacimab, and donidalorsen as first-line options. The 2026 pediatric guideline recommends lanadelumab or plasma-derived C1 inhibitor for children aged between 6 and 12 years, and adds berotralstat and garadacimab for adolescents aged 12 years or older. Both guidelines recommend supplying on-demand treatment for at least 2 attacks during prophylaxis, and the Vázquez et al. guideline recommends management by physicians with expertise in HAE supported by a referral center.

Onvuzosiran is an investigational small interfering RNA and appears in no guideline list of first-line agents. The sponsor is developing it for prevention of HAE attacks as a subcutaneous injection every 3 or 6 months, both intervals being studied in the phase 3 STOP-HAE trial, and a 2025 review describes it as in development for long-term prophylaxis in HAE type I/II. STOP-HAE requires participants to complete any washout of long-term prophylaxis before screening and to have access to an acute therapy, so its results will describe onvuzosiran as the only long-term prophylactic agent, compared with placebo, with on-demand treatment available. The sources do not state whether onvuzosiran would be self-administered or given by a health care professional; the guideline states that self-administration and home therapy are available for current agents including lanadelumab, garadacimab, and donidalorsen.

Other prophylactic agents in late-stage development include navenibart, a plasma kallikrein inhibitor dosed subcutaneously every 3 or 6 months in a phase 3 trial with top-line results expected in Q3 2027; deucrictibant XR, with an NDA submission planned for the first half of 2027; lonvoguran ziclumeran, intended as a single-dose therapy, with a PDUFA target action date of March 10, 2027; and BW-20805, a second prekallikrein-directed siRNA dosed every 12 or 24 weeks in a study of 25 participants with HAE.

Heterogeneity of treatment effect

No evidence found.

Care management intervention strategies
Other product development or post-marketing obligations required by the FDA

Not applicable.

Ongoing post-approval monitoring

Not applicable.

Expected outcomes of therapy